Mouse monoclonal antibody to C
ell division control protein 6 homolog【IMD-6]: IgG/Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG/Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG- 询价
- Biosensis
- 澳大利亚
- M-1185-100-E
- 2025年07月07日
- Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 小鼠
- Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant human Cell division control protein 6 homolog (CDC6)
- 亚型：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 形态：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 保存条件：
厂家建议常温运输。自购买之日起，保持冻干粉状态于2-4℃，有效期为12个月。抗体溶解之后，建议分装保存于-20℃，请避免反复冻融。
- 克隆性：
单克隆
- 标记物：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 适应物种：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 保质期：
根据订购时间与产品批次判定，欢迎联系艾美捷咨询确认
- 抗原来源：
小鼠
- 目录编号：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 级别：
一抗
- 库存：
小鼠来源毒性抗体：细胞分裂控制蛋白6同源物【IMD-6】：IgG
- 供应商：
艾美捷
- 宿主：
小鼠
- 应用范围：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 浓度：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 靶点：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 抗体英文名：
Mouse monoclonal antibody to Cell division control protein 6 homolog【IMD-6]: IgG
- 抗体名：
小鼠来源毒性抗体：细胞分裂控制蛋白6同源物【IMD-6】：IgG
- 规格：
100ug
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验ANTIBODY BINDING TO PROTEIN A AND PROTEIN G
A Protein G Human IgG1 ++++ ++++ Human IgG2 ++++ ++++ Human IgG3 - ++++ Human IgG4 ++++ ++++ Mouse IgG1 + ++++ Mouse IgG
Rapid Isotyping of Mouse Monoclonal Antibodies
, isotyping is useful to control lot to lot consistency, detect contamination by another antibody, and identify hybridoma switch variants (see Notes 2 –8 for further comment on applications). Table 1 Isotype-Dependent Properties of Monoclonal
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
